Sanofi's rilzabrutinib receives FDA breakthrough and Japan orphan designations for rare anaemia

AbbVie submits FDA and EMA applications for new upadacitinib indication in NSV

WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals

I Peace generates human iPS cells from NKT cells and offers them for research use

Repertoire Immune Medicines teams up with Eli Lilly and Company to develop tolerizing therapies for autoimmune diseases

Formation Bio acquires worldwide rights to FHND5032 from CTFH

WuXi Biologics collaborates with Sinorda Biomedicine for antibody development

Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE

HanchorBio partners with WuXi Biologics for development and manufacturing of next-gen bi- and multi-functional fusion programmes

Roivant to announce Q3 2026 financial results

AbbVie licenses PD-1/VEGF bispecific antibody RC148 from RemeGen in multi-billion dollar oncology deal

HUTCHMED reports positive Phase III results for sovleplenib in wAIHA

Physiomics secures follow-on UK contract for Phase 2 study support

Amgen's UPLIZNA receives US FDA approval

Physiomics secures new contract with Numab Therapeutics for preclinical antibody development